Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CEL-SCI Corporation (NYSE American: CVM) is a clinical-stage biotechnology company focused on the research and development of immunotherapy treatments for cancer. The company operates within the biotechnology and oncology drug development industries, with its activities centered on harnessing the immune system to improve cancer treatment outcomes. CEL-SCI does not currently have approved commercial products and does not generate recurring product revenue; its operations are primarily funded through equity financings.
The company’s core product candidate is Multikine® (Leukocyte Interleukin, Injection), an investigational immunotherapy designed to be administered prior to standard cancer treatments such as surgery, radiation, or chemotherapy. CEL-SCI’s strategic positioning is based on its focus on immune modulation before tumor removal, which it asserts is a differentiated approach compared with post-surgical or metastatic-stage immunotherapies. The company was founded in 1983 and has evolved from a diversified biotechnology research entity into a company almost entirely focused on the clinical development and regulatory advancement of Multikine for head and neck cancers.
Business Operations
CEL-SCI’s business operations are organized around a single primary operating segment: oncology immunotherapy development. The company’s activities include clinical trial management, regulatory engagement, manufacturing oversight, and intellectual property management related to Multikine. All revenues to date have been non-operating in nature, primarily derived from interest income, while operating expenses are driven by research and development and general administrative costs.
The company conducts its clinical development activities both domestically and internationally, including large, late-stage clinical trials conducted across multiple countries. CEL-SCI controls proprietary manufacturing processes for Multikine through its dedicated manufacturing facility, which is designed to meet regulatory standards for biologics production. The company does not report material joint ventures or revenue-generating partnerships, and its operations are conducted primarily through the parent entity, CEL-SCI Corporation, and its wholly owned subsidiaries established to support international clinical and operational functions.
Strategic Position & Investments
CEL-SCI’s strategic direction is centered on achieving regulatory approval for Multikine as a front-line therapy for newly diagnosed head and neck squamous cell carcinoma. Its primary growth initiative is the advancement, analysis, and regulatory submission of data from its completed global Phase 3 clinical trial. The company’s long-term strategy is to position Multikine as a platform immunotherapy that could potentially be expanded into additional cancer indications, subject to regulatory outcomes and future clinical studies.
The company’s investments are largely concentrated in internal research and development rather than external acquisitions. CEL-SCI has historically not pursued a diversified portfolio strategy and does not report ownership of multiple operating portfolio companies. Its emerging focus remains within immune-based oncology treatments, with no verified expansion into unrelated therapeutic areas. Any future partnerships or licensing arrangements remain contingent on regulatory milestones and have not been conclusively established based on available public disclosures.
Geographic Footprint
CEL-SCI is headquartered in the United States, with its principal executive offices and manufacturing operations located in Virginia. While the company’s corporate footprint is relatively small, its clinical and regulatory activities extend internationally through clinical trial sites across Europe, Asia, and other global regions involved in its Phase 3 studies.
The company’s international presence is primarily operational rather than commercial, as it does not currently market approved products. Its global influence is therefore tied to clinical research, regulatory engagement, and investigator collaboration rather than sales or distribution infrastructure. CEL-SCI does not report permanent large-scale commercial operations outside the United States.
Leadership & Governance
CEL-SCI is led by a management team with long-standing involvement in the company and experience in biotechnology product development, regulatory strategy, and corporate finance. The leadership emphasizes a focused, single-product strategy and long-term value creation through regulatory approval rather than near-term commercialization.
Key executives include:
- Geert Kersten – Chief Executive Officer
- Geert Kersten – President
- Geert Kersten – Chairman of the Board
- Erik S. Kraus – Chief Financial Officer
- Vyacheslav Klimov – Vice President of Operations
- Peter Shapiro – Director
The governance structure reflects a centralized leadership model, with the CEO holding multiple senior roles. The company’s stated strategic vision emphasizes disciplined capital management, regulatory compliance, and the advancement of Multikine as a novel immunotherapy approach in oncology.